Le Lézard
Classified in: Health, Science and technology
Subject: TDS

@-Health Unveils the Future of E-health at CES 2018



AIX-EN-PROVENCE, France, December 8, 2017 /PRNewswire/ --

Stand 50023 - Espace Provence Alpes Côte d'Azur 

@-Health, a company specializing in e-cardiology, will be participating for the first time at the CES (Consumer Electric Show), the unmissable event of the world's high-tech, to be held from January 9-12, 2018 in Las Vegas. With the support of French Tech Aix-Marseille, the Aix-based company will present CardioNexion, the first connected medical device for the ultra-early detection and analysis, in real time and continuously, of all cardiovascular pathologies.

     (Logo: http://mma.prnewswire.com/media/617024/Health_Logo.jpg )

Cardiovascular disease is the leading cause of death worldwide according to WHO. In the face of this global public health challenge, @ -Health is setting its sights on being a leading player. By participating in CES 2018, the company intends to demonstrate the relevance of CardioNexion to US investors and find potential partners.

Recall that CardioNexion is a connected medical device that continuously monitors real-time cardiac activity by specialists in cardiology.

It can detect and prevent with certainty any pathology whose first sign is a change in heart rate: stroke, atrial fibrillation, heart failure, sudden infant death, influenza... well before the first symptoms appear.

CardioNexion is also a new tool for practitioners. Indeed, it allows the attending physician to prescribe appropriate treatment and control its effectiveness in real time: a world first!

Specifically, for the patient, the device is in the form of a T-shirt or bra with smart sensors that monitor in real time 24/24 - 365 / day / year many essential data for its health.

This totally ambulatory, non-invasive and autonomous device allows to have the same medical supervision as in an intensive care unit. Via the patient's smartphone, anonymized data, collected 24 hours a day, are sent to secure servers, where they will be analyzed using a proprietary algorithm. They are then transported to a surveillance platform where a team of cardiologists and intensive care unit nurses are ready to respond. If a problem is detected, the patient's doctor is notified. In the most serious cases, "911" is directly called.

FOR MORE INFORMATION 


These press releases may also interest you

at 13:36
Experts in pediatric heart disease from multiple centers worldwide are sharing their findings at a large national conference sponsored by the Cardiac Center at Children's Hospital of Philadelphia (CHOP). Cardiology 2018, the 21th Annual Update on...

at 12:46
Terumo BCT announced today that it will be the exclusive distributor for Stafa Cellular Therapy (StafaCT), a U.S.-based software developer. StafaCT software supports healthcare facilities and cell labs as they manage each phase of the cellular...

at 12:15
JUUL Labs, Inc. today announced results from a preliminary study on the temperature regulation and harmful and potentially harmful constituents (HPHCs) of JUUL's Virginia Tobacco 5% nicotine-e-liquid filled pod. The findings, "Characterization of...

at 10:00
A new study reveals that most adults hold beliefs about the harms from nicotine that are opposite from what scientists have concluded. The findings, presented at the Society for Research on Nicotine and Tobacco 24th Annual Meeting in Baltimore,...

at 07:34
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, announces that it has filed a class action against MiMedx Group, Inc. ("MiMedx" or the "Company") and certain of its officers for violations of...

at 03:00
SAN RAFAEL, Calif., Feb. 24, 2018 /PRNewswire-PRWeb/ -- Michael Moskowitz, MD, MPH and Randy Perretta of Anandamedicine, Bill Heriot of Liposome Formulations Inc, George Bianchini of Medi-Cone and Leonard Leinow of Synergy Wellness have joined to...




News published on 7 december 2017 at 20:00 and distributed by: